Pre-Christmas milestone for Dimerix as ACTION3 phase III fully recruited

DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Recruitment successfully completed in Dimerix’ ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressure…

Pre-Christmas milestone for Dimerix as ACTION3 phase III fully recruited

Recruitment complete in Dimerix’s ACTION3 phase III clinical trial of DMX-200 in rare kidney disease focal segmental glomerulosclerosis The global trial has recruited and dosed its target 286th adult patient with 69 patients already completing the full two-year treatment period Dimerix and US partner Amicus Therapeutics to seek FDA feedback on trial endpoints following PARASOL findings   Special Report: Dimerix has achieved a key catalyst before…